Press Releases

November 22, 2023

Regulatory

Nomination Committee appointed ahead of AGM 2024 in SynAct Pharma AB

November 14, 2023

Non Regulatory

SynAct Pharma comments on ownership changes in Bioinvest Aps

November 1, 2023

Regulatory

SynAct Pharma announces evaluation of the 4-week RESOLVE P2a clinical trial in moderate to severely active rheumatoid arthritis patients with an incomplete response to methotrexate

October 31, 2023

Regulatory

Change in number of shares and votes in SynAct Pharma

October 24, 2023

Regulatory

SynAct Pharma publishes Q3 2023 interim report

October 12, 2023

Regulatory

SynAct Pharma AB publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm

October 11, 2023

Regulatory

SynAct Pharma AB carries out a directed issue of shares and warrants raising initial gross proceeds of SEK 60.5 million

October 9, 2023

Non Regulatory

Invitation to SynAct’s interim report Q3 2023 presentation

October 3, 2023

Non Regulatory

SynAct Pharma announces additional data from the EXPAND P2b clinical trial further supporting efficacy and activity seen in patients with elevated CRP

September 12, 2023

Regulatory

SynAct Pharma announces additional data from the EXPAND P2b clinical trial and identifies population with responsiveness to resomelagon

September 4, 2023

Regulatory

SynAct Pharma announces top line data from the 12-week EXPAND P2b clinical trial in severely active newly diagnosed rheumatoid arthritis patients

August 17, 2023

Non Regulatory

SynAct Pharma completes dosing in part A of combined Phase 2a/b RESOLVE study of resomelagon (AP1189) in rheumatoid arthritis (RA)

August 4, 2023

Regulatory

SynAct Pharma publishes Q2 2023 interim report

July 21, 2023

Non Regulatory

Invitation to SynAct Pharma’s interim report Q2 2023 presentation

July 20, 2023

Non Regulatory

SynAct Pharma completes patient recruitment for part A of combined Phase 2a/b RESOLVE study of resomelagon (AP1189) in rheumatoid arthritis (RA)

July 14, 2023

Non Regulatory

SynAct Pharma announces the completion of dosing in the Phase 2b EXPAND study of resomelagon (AP1189) in early severe rheumatoid arthritis patients

June 29, 2023

Non Regulatory

SynAct Pharma to present at 19th World Congress of Basic and Clinical Pharmacology in Glasgow on July 4

May 31, 2023

Non Regulatory

SynAct Pharma to present at the 2023 BIO International Convention

May 29, 2023

Non Regulatory

SynAct Pharma to participate at ABGSC Life Science Summit May 30

May 25, 2023

Regulatory

Bulletin from the annual general meeting in SynAct Pharma AB on May 25, 2023

May 15, 2023

Regulatory

SynAct Pharma appoints Björn Westberg as CFO

May 5, 2023

Regulatory

SynAct Pharma publishes Q1 2023 interim report

April 24, 2023

Regulatory

SynAct Pharma completes patient recruitment for Phase 2b EXPAND study of AP1189 in early severe Rheumatoid Arthritis

April 17, 2023

Non Regulatory

SynAct Pharma announces program for the upcoming Capital Markets Day in Stockholm on May 5, 2023

April 13, 2023

Regulatory

Notice of annual general meeting in SynAct Pharma AB

April 13, 2023

Regulatory

SynAct Pharma publishes Annual Report 2022

April 3, 2023

Regulatory

The Nomination Committee of SynAct Pharma proposes Uli Hacksell as new Chairman and Thomas von Koch as new Board member

April 3, 2023

Regulatory

SynAct Pharma appoints Torbjørn Bjerke as new CEO

March 30, 2023

Non Regulatory

SynAct Pharma introduces resomelagon as generic name for AP1189

March 28, 2023

Non Regulatory

SynAct Pharma to host a Capital Markets Day in Stockholm on May 5, 2023

March 23, 2023

Non Regulatory

SynAct strengthens its patent portfolio

February 17, 2023

Regulatory

SynAct Pharma publishes Annual Results for 2022

February 1, 2023

Regulatory

Patrik Renblad is leaving SynAct Pharma and the search for a new CFO has been initiated

January 31, 2023

Regulatory

Change in number of shares and votes in SynAct Pharma

January 16, 2023

Regulatory

SynAct Pharma completes the acquisition of TXP Pharma

January 12, 2023

Regulatory

Bulletin from the extraordinary general meeting of SynAct Pharma AB

December 30, 2022

Regulatory

Change in number of shares and votes in SynAct Pharma

December 22, 2022

Regulatory

Change in Nomination Committee prior to AGM 2023 in SynAct Pharma

December 16, 2022

Non Regulatory

SynAct Pharma initiates dosing in the RESOLVE study in DMARD-IR RA

December 14, 2022

Non Regulatory

SynAct Pharma’s COO sells shares to cover tax on holdings

December 12, 2022

Regulatory

Notice of extraordinary general meeting in SynAct Pharma AB

December 12, 2022

Regulatory

SynAct Pharma to make strategic acquisition of Swiss biotech company TXP Pharma

December 12, 2022

Regulatory

SynAct Pharma carries out a directed share issue of SEK 80 million in connection with the acquisition of TXP Pharma

November 4, 2022

Regulatory

SynAct Pharma publishes Q3 2022 interim report

November 1, 2022

Non Regulatory

SynAct Pharma receives IND clearance from the FDA for Phase 2a/b trial of AP1189 in RA

October 21, 2022

Regulatory

Nomination Committee appointed ahead of AGM 2023 in SynAct Pharma AB

September 30, 2022

Non Regulatory

SynAct Pharma submits IND for US Phase 2a/b clinical trial

September 27, 2022

Non Regulatory

SynAct Pharma enrolls first patient in Phase 2b trial of AP1189 in RA

September 14, 2022

Non Regulatory

Approval of amended study protocol for the Phase 2a study in iMN

August 25, 2022

Non Regulatory

CTA approved for the Phase 2b study EXPAND

August 16, 2022

Non Regulatory

Resomelagon proposed international nonproprietary name (INN) for AP1189

August 5, 2022

Regulatory

SynAct Pharma publishes Q2 2022 interim report

July 21, 2022

Non Regulatory

SynAct Pharma improves the design of the ongoing Phase 2a study in iMN

July 12, 2022

Regulatory

Trading in SynAct Pharma’s shares on Nasdaq Stockholm commences today

July 8, 2022

Regulatory

SynAct Pharma AB publishes prospectus for list change to Nasdaq Stockholm

June 29, 2022

Regulatory

SynAct Pharma recieves pre-IND response from the US FDA

June 28, 2022

Regulatory

SynAct Pharma AB has been approved for listing on Nasdaq Stockholm

June 21, 2022

Non Regulatory

SynAct Pharma submits CTA for Clinical Phase 2b Study in RA

May 30, 2022

Regulatory

SynAct Pharma publishes Q1 2022 interim report

May 20, 2022

Regulatory

Bulletin from the annual general meeting in SynAct Pharma AB on May 20, 2022

May 18, 2022

Non Regulatory

Synact Pharma to present at the ABGSC Life Science Summit

May 12, 2022

Regulatory

Last day of trading in paid subscribed shares (Sw. betalda tecknade aktier) in SynAct Pharma AB

May 4, 2022

Non Regulatory

SynAct Pharma completes clinical pharmacokinetic test of AP1189 tablet

April 29, 2022

Regulatory

SynAct Pharma AB publishes Annual Report 2021

April 25, 2022

Regulatory

SynAct announces outcome of rights issue

April 20, 2022

Regulatory

Notice of annual general meeting in SynAct Pharma AB

April 1, 2022

Non Regulatory

SynAct publishes prospectus in connection with a fully guaranteed rights issue

March 28, 2022

Regulatory

Bulletin from the extraordinary general meeting on March 28, 2022, in SynAct Pharma AB

March 28, 2022

Regulatory

SynAct resolves on a fully guaranteed rights issue of approximately SEK 150 million

March 9, 2022

Regulatory

Notice of extraordinary general meeting in SynAct Pharma AB

March 9, 2022

Regulatory

The Nomination Committee proposes Kerstin Hasselgren as a new board member of SynAct Pharma AB

February 11, 2022

Regulatory

Annual Results 2021

January 7, 2022

Non Regulatory

SynAct Pharma appoints Patrik Renblad as CFO

December 7, 2021

Non Regulatory

SynAct Pharma’s board and management extend lock-up agreements

December 2, 2021

Non Regulatory

SynAct Pharma announces additional data from the BEGIN study

December 1, 2021

Non Regulatory

SynAct Pharma strengthens its patent portfolio for AP1189 following an Intention to Grant from the European Patent Office

November 30, 2021

Regulatory

SynAct Pharma’s AP1189 meets primary endpoint and demonstrates favorable safety profile in Rheumatoid Arthritis patients with active joint disease in the Phase 2a BEGIN study

November 23, 2021

Non Regulatory

SynAct Pharma reports positive PK data on AP1189 tablets

November 19, 2021

Non Regulatory

SynAct Pharma announces Nomination Committee in respect of AGM 2022

November 12, 2021

Regulatory

Interim report Q3 2021

November 11, 2021

Non Regulatory

SynAct Pharma takes advantage of new toxicology results and new tablet formulation to re-design and optimize the study programme with AP1189 in Nephrotic Syndrome

November 5, 2021

Non Regulatory

AP1189 can be dosed for three months in future clinical studies

October 25, 2021

Non Regulatory

SynAct Pharma completes dosing in the BEGIN study

October 15, 2021

Non Regulatory

SynAct Pharma doses first subject in study with new AP1189 tablets

September 24, 2021

Regulatory

SynAct Pharma completes patient recruitment to the Phase 2a BEGIN study of AP1189 in early severe Rheumatoid Arthritis

August 27, 2021

Regulatory

SynAct Pharma: Interim Report January-June 2021 August 27, 2021 (Q2 2021 Report included)

August 27, 2021

Regulatory

SynAct Pharma: Interim Report January-June 2021 August 27, 2021

August 27, 2021

Regulatory

SynAct Pharma Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis

August 25, 2021

Regulatory

SynAct strengthens IP portfolio – Grant of key European patent covering AP1189

August 20, 2021

Regulatory

SynAct Pharma to present new data on AP1189 for the treatment of rheumatoid arthritis at ACR Convergence 2021

August 6, 2021

Regulatory

SynAct Pharma strengthens its organization with two key recruitments

July 7, 2021

Announcing additional Data from the Phase 2a Trial of AP1189 in Covid-19 Infected Patients

July 7, 2021

Regulatory

SynAct Pharma Appoints Anders Dyhr Toft, MD, Ph.D., as Chief Medical Officer

July 7, 2021

Regulatory

SynAct Pharma AB Announces Additional Data from the Phase 2a Trial of AP1189 in Covid-19 Infected Patients and Reminds of Management Call to Discuss Results

July 2, 2021

Regulatory

SynAct Pharma Hosts Conference Call on Positive Data from a Phase 2a Trial of AP1189 in Covid-19 Infected Patients

June 30, 2021

Regulatory

SynAct Pharma AB Announces Positive Data from a Phase 2a Trial of AP1189 in Covid-19 Infected Patients

June 23, 2021

Regulatory

SynAct Pharma Files Patent Applications Related to AP1189 Derived APIs and Oral Formulations

June 1, 2021

Regulatory

SynAct Pharma completes recruitment and dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients

May 21, 2021

Regulatory

Bulletin from the annual general meeting in SynAct Pharma AB on 21 May 2021

May 21, 2021

Regulatory

Synact Pharma to present at upcoming investor conference

May 14, 2021

Regulatory

SynAct Pharma AB: SynAct Pharma initiates collaboration on pharmacogenetic aspects of AP1189 compound in Rheumatoid arthritis with Barts and London School of Medicine, Queen Mary University of London.

May 12, 2021

Regulatory

SynAct Pharma partners with Örebro University to study cardiovascular disease

May 5, 2021

Regulatory

SynAct Pharma: Interim report January-March 2021

May 4, 2021

Regulatory

SynAct Pharma Board and Management extend lock-up period   UK Version

May 4, 2021

Regulatory

SynAct Pharma expands AP1189 BEGIN study in Rheumatoid Arthritis UK Version

April 30, 2021

Regulatory

SynAct Pharma to participate at Kempen’s virtual Life Sciences Conference

April 19, 2021

Regulatory

SynAct Pharma shareholders propose Marina Bozilenko as new board member

April 19, 2021

Regulatory

Notice of annual general meeting in SynAct Pharma AB

April 13, 2021

Regulatory

SynAct strengthens IP portfolio – Receives “Intention to Grant” from the European Patent Office for a key patent covering AP1189 English version

March 18, 2021

Regulatory

SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version

March 1, 2021

Regulatory

SynAct Pharma’s CFO and board member sell shares to cover taxes on holdings

February 12, 2021

Non Regulatory

Year-end Report 2020

February 11, 2021

Regulatory

SynAct Pharma Names James Knight as Chief Business Officer – Already published in Swedish today

February 5, 2021

Regulatory

SynAct carries out a directed share issue and raises proceeds of SEK 80 million

February 4, 2021

Regulatory

SynAct explores the conditions for carrying out a directed share issue – English version – Published today 17.31 CET

February 4, 2021

Regulatory

SynAct Pharma prepares move to Nasdaq Stockholm – English version – Published today at 17.31 CET

January 26, 2021

Regulatory

SynAct Pharma names Thomas Boesen as Chief Operating Officer

January 11, 2021

Regulatory

Published in English – already published 11:18 CET today Disclosure notice in SynAct Pharma AB

November 13, 2020

Regulatory

SynAct Pharma publishes Q3 2020 interim report (in Swedish)

November 9, 2020

Regulatory

SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis

November 6, 2020

Regulatory

Bulletin from the extraordinary shareholders’ meeting in SynAct Pharma AB

October 20, 2020

Regulatory

Notice of extraordinary shareholders’ meeting in SynAct Pharma AB

October 20, 2020

Regulatory

Shareholders of SynAct Pharma proposes Uli Hacksell as new board member

October 19, 2020

Regulatory

SynAct Pharma terminates agreement for liquidity providing

October 12, 2020

Regulatory

English version of PR published 20201012 at 07.33AM     SynAct Pharma completes part 1 of clinical phase II study with AP1189 in Rheumatoid Arthritis

September 23, 2020

Regulatory

Swedish version of press release published earlier today. SynAct Pharma initierar fas II-studie med AP1189 för behandling av ARDS i COVID-19-patienter

September 23, 2020

Regulatory

SynAct Pharma Initiates Phase II Study with AP1189 for the Treatment of ARDS in COVID-19 Patients

September 3, 2020

Regulatory

SynAct Pharma informs that the recruitment to part 1 in the Clinical Phase II study with AP1189 in Rheumatoid Arthritis is completed

September 1, 2020

Regulatory

SynAct Pharma Informs about Termination of Coverage Agreement with Redeye

August 28, 2020

Regulatory

SynAct Pharma publishes Q2 2020 interim report (in Swedish)

August 28, 2020

Regulatory

SynAct Pharma Initiates RESOVIR: Scientific and clinical Collaboration to Explore AP1189 in Viral Infections

July 27, 2020

Regulatory

Synact Pharma announces outcome in the exercise of warrants, will receive approximately MSEK 32.4

July 15, 2020

Regulatory

SynAct Pharma AB: Update on SynAct Pharma´s Clinical Phase II study with AP1189 in Rheumatoid Arthritis

June 30, 2020

Regulatory

SynAct Pharma announces that the exercise period for warrants of the TO 2 series will start on July 1, 2020

June 29, 2020

Regulatory

SynAct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome

June 25, 2020

Regulatory

SynAct Pharma’s Board of Directors and management sign subscription commitment for warrant exercise of series TO 2

June 2, 2020

Regulatory

SynAct Pharma´s clinical trial application for AP1189 in Nephrotic Syndrome approved by the Danish Medical Agency

May 25, 2020

Regulatory

SynAct Pharma files patent application for combination of AP1189 and Methotrexate for treatment of RA and other arthritic diseases

May 5, 2020

Regulatory

SynAct presents initial data from the first part of the Phase II study within RA and gives an update on its progression

May 5, 2020

Regulatory

SynAct Pharma publishes Q1 2020 interim report (in Swedish)

April 3, 2020

Regulatory

SynAct Pharma applies for patent for AP1189 within COVID-19

April 2, 2020

BIOSTOCK: Synact Pharma on expansion into Covid-19 (also available in Swedish)

March 31, 2020

Regulatory

SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome

March 31, 2020

Regulatory

Translation – UK version of Swedish press release – published 08.00 AM. today – SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19

February 11, 2020

Regulatory

SynAct Pharma publishes Annual Results for 2019 (in Swedish)

November 15, 2019

Regulatory

SynAct Pharma publishes Q3 2019 interim report (in Swedish)

November 11, 2019

Non Regulatory

SynAct receives approval from the Swedish Medical Product Agency and the Swedish Ethical Review Authority regarding the clinical Phase IIa study with AP1189

October 28, 2019

Non Regulatory

Redeye: Adding an indication

October 21, 2019

Regulatory

SynAct conducts private placement and fully guaranteed rights issue with the aim of increasing the commercial value of AP1189

August 30, 2019

Regulatory

SynAct Pharma publishes Q2 2019 interim report (in Swedish)

May 2, 2019

Regulatory

SynAct Pharma AB secures bridge loan financing for AP1189

April 24, 2019

Regulatory

SynAct Pharma publishes Q1 2019 interim report (in Swedish)

April 17, 2019

Regulatory

SynAct publishes annual report and consolidated accounts for 2018

April 9, 2019

Regulatory

Notice of Annual General Meeting of SynAct Pharma AB

March 29, 2019

Regulatory

SynAct applies for start of phase IIa clinical study in patients with active arthritis

March 21, 2019

Regulatory

Bulletin from the Extraordinary General Meeting at SynAct Pharma AB

February 25, 2019

Non Regulatory

John Haurum and Terje Kalland are proposed as new members of the Board of Directors in SynAct Pharma AB

February 19, 2019

Regulatory

Notice of Extraordinary General Meeting of SynAct Pharma AB (publ)

February 13, 2019

Regulatory

Changes in the Board of Directors of SynAct Pharma

February 11, 2019

Regulatory

Year-end report for the financial year 2018

February 11, 2019

Regulatory

SynAct reported positive phase I results for candidate drug AP1189 and prepared funding for broadened phase II programmes

December 21, 2018

Regulatory

Dosing with candidate drug AP1189 in multiple-dose part of the Phase I study completed

December 10, 2018

Regulatory

SynAct’s candidate drug AP1189 exhibits continued favourable safety and plasma profiles in the multiple-dose part of the Phase I study

November 16, 2018

Regulatory

Interim report Q3 2018

October 22, 2018

Regulatory

SynAct Pharma announced that AP1189 exhibits a favourable plasma profile in the Phase I study’s initial multiple-dose part

September 13, 2018

Regulatory

SynAct Pharma announced the start of the multiple-dose part of the Phase I study with AP1189

August 30, 2018

Regulatory

Interim report 01/01/2018 – 30/06/2018

August 20, 2018

Regulatory

SynAct Pharma announced positive data from preclinical study in nephrotic syndrome with candidate drug AP1189

July 23, 2018

Regulatory

SynAct Pharma obtains regulatory approval for the implementation of the multiple-dose part in Phase I study with candidate drug AP1189

June 18, 2018

Non Regulatory

SynAct Pharma AB responds to questions about the further development of candidate drug AP1189

June 12, 2018

Regulatory

SynAct Pharma adapts the continued clinical development programme for AP1189 based on new results from the Phase I study

May 30, 2018

Regulatory

Last day of trading in BTA

May 15, 2018

Regulatory

Bulletin from the Annual General Meeting of SynAct Pharma AB

May 14, 2018

Regulatory

Synact Pharma rights issue oversubscribed

April 19, 2018

Regulatory

SynAct Pharma publishes Q1-2018 Report

April 19, 2018

Regulatory

The subscription period for SynAct Pharma AB’s rights issue begins today

April 18, 2018

Regulatory

SynAct Pharma publishes the annual report for 2017 financial year

April 17, 2018

Non Regulatory

SynAct Pharma AB holds investor meetings in connection with the rights issue

April 12, 2018

Regulatory

Notice of Annual General Meeting of SynAct Pharma AB (publ)

April 11, 2018

Regulatory

SynAct Pharma AB (publ) publishes memorandum before the rights issue

April 10, 2018

Regulatory

Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)

April 6, 2018

Non Regulatory

Market announcement 86/18 – Information about the rights issue for SynAct Pharma AB

March 26, 2018

Regulatory

SynAct Pharma’s interim report for Q1 will be published on 19 April 2018

March 23, 2018

Regulatory

SynAct Pharma proposes a rights issue of SEK 22.4 million in order to increase the market potential for AP1189.

March 23, 2018

Regulatory

Notice of Extraordinary General Meeting of SynAct Pharma AB (publ)

February 13, 2018

Regulatory

Year-end report 2017

November 3, 2017

Regulatory

Interim report Q3 2017

October 6, 2017

Regulatory

CEO, CFO and CSO increase their shareholdings in SynAct

October 3, 2017

Regulatory

The first part of the clinical Phase I study with SynAct Pharma’s drug candidate AP1189 successfully completed

August 31, 2017

Regulatory

Half-yearly report 01-01-2017 – 30-06-2017

June 7, 2017

Regulatory

SynAct Pharma announces the start of Clinical Phase I study

May 11, 2017

Regulatory

Bulletin from the Annual General Meeting of SynAct Pharma AB (publ)

May 11, 2017

Regulatory

Interim report Q1 2017   Synact Pharma

May 10, 2017

Regulatory

SynAct Pharma AB receives approval to start Clinical Phase I study with AP1189 – a new potential treatment for psoriatic arthritis

April 27, 2017

Regulatory

Utilisation of subscription options registered with Swedish Companies Registration Office

April 25, 2017

Regulatory

SynAct Pharma AB provides an update on the clinical development plan for AP1189

April 20, 2017

Regulatory

Annual Report 2016

April 11, 2017

Regulatory

Notice of Annual General Meeting of SynAct Pharma AB (publ)

March 31, 2017

Regulatory

SynAct Pharma AB will raise 1,007,539.20 SEK through the utilisation of series TO 1 subscription options

March 17, 2017

Regulatory

Reminder of the utilisation of series TO 1 subscription options

March 9, 2017

Regulatory

SynAct Pharma AB retains subscription rights for series TO 1subscription option

March 9, 2017

Regulatory

The utilisation period of SynAct Pharma AB’s series TO 1 subscription options starts today

February 22, 2017

Regulatory

SynAct Pharma AB has received approval from the Ethics Committee and continues its dialogue with the French Medicines Agency

February 9, 2017

Regulatory

SynAct Pharma Year-end report 2016

January 27, 2017

SynAct presented in Copenhagen at Sedermera Investor Event

December 9, 2016

Non Regulatory

SynAct Pharma submits application for start of Phase I clinical study

November 28, 2016

Non Regulatory

SynAct Pharma recruits specialists for the early clinical studies

November 4, 2016

Non Regulatory

Interim report 3, 2016

October 28, 2016

Non Regulatory

SynAct Pharma fulfilled its commitments to the financier Seed Fund CapNova by a one-time payment

August 31, 2016

Non Regulatory

Half-yearly Report 2016

July 11, 2016

Non Regulatory

Trading starts in SynAct Pharma AB’s shares and subscription options on Aktietorget today

July 4, 2016

Non Regulatory

Market Announcement 174/16 – SynAct Pharma AB listed on Aktietorget 11 July 2016 – corrected version

June 14, 2016

Non Regulatory

SynAct Pharma AB’s issue before listing oversubscribed

June 3, 2016

Non Regulatory

Publication of additional prospectus

May 30, 2016

Non Regulatory

Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)

May 24, 2016

Non Regulatory

Today the subscription period for SynAct Pharma AB’s issue opens, before the planned listing on Aktietorget

May 24, 2016

Non Regulatory

Publication of SynAct Pharma AB’s prospectus in connection with the issue ahead of planned listing on Aktietorget

May 12, 2016

Non Regulatory

Notice of Extraordinary General Meeting of SynAct Pharma AB (publ)

May 9, 2016

Non Regulatory

Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)

April 21, 2016

Non Regulatory

Notice of Extraordinary General Meeting of SynAct Pharma AB (publ)